EHA Studio Actueel Deel 2

In dit tweede deel van EHA Studio Actueel bespreekt Tom van 't Hek samen met dr. Wilfried Roeloffzen, dr. Elly Lugtenburg, dr. Marjolein van der Poel en dr. Wouter Plattel het belangrijkste congresnieuws op het gebied van Hodgkin lymfoom, Non-Hodgkin lymfoom en Multipel Myeloom. 

Bent u geïnteresseerd in een specifiek onderwerp uit dit programma? Klik dan rechts in de videospeler voor de hoofdstukindeling. 

Bekijk hier de interviews en EHA Studio Actueel Deel 1

De volgende abstracts komen aan bod: 

Hodgkin lymfoom

• s225 - The randomized study GHSG HD21 shows superior tolerability and efficacy of BRECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma
• S228 - Gonadal function recovery and fertility in the phase III German Hodgkin study group HD21 trial
• S226 - EORTC-1537-COBRA: very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study
• S227 - Serum tarc combined with FDG-PET imaging improves interim response evaluation in classical Hodgkin lymphoma: a retrospective analysis of German Hodgkin study group HD16 and HD18 trials
• S244 - An abbreviated course of A_AVD followed bij nivolymab consolidation for frontline thyerapy in patients with limited stage Hodgkin lymphoma

Non-Hodgkin lymfoom

• s247 valemetostat monotherapy in patients with relapsed or refractory peripheral t-cell lymphomas: efficacy by prior lines of treatment and last treatment outcome from the valentine-ptcl01 study
• lba438 glofitamab plus gemcitabine and oxaliplatin (glofit-gemox) for relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl): results of a global randomized phase iii trial (starglo)
• s231 glofitamab monotherapy in patients with heavily pretreated relapsed or refractory mantle cell lymphoma: updated analysis from a phase i/ii study
  tycel phillips (ann arbor, united states of america)
• s233 mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥ 3 years of follow-up: subgroup analysis of pivotal phase II study.
• s234 epcoritamab induces deep responses in relapsed or refractory (R/R) follicular lymphoma (FL): safety and pooled efficacy data from EPCORE NHL-1 pivotal and cycle (C) 1 optimization (opt) FL cohorts.
• s236 feasibility and clinical efficacy of atezolizumab consolidation in high risk diffuse large b-cell lymphoma: final analysis of the hovon 151. 
• s243 seven-day vein-to-vein point-of-care–manufactured cd19 car t cells (glpg5101) in relapsed/refractory non-hodgkin lymphoma: results from the phase 1/2 atalanta-1 trial
• s272 lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by asct as second-line treatment in patients with r/r large b-cell lymphoma: 3-year follow-up of transfor
• s242 real-world assessment of anti-cd19 car-t cells in patients aged 75 years and older with relapsed or refractory large b cell lymphoma: a lysa study from the descar-t registry
• s288 efficacy and toxicity of anti-cd19 car t-cells in patients with primary and secondary cns-lymphoma – an analysis of the lymphoma working party of the ebmt and the gocart coalition

Multipel myeloom

• s201 daratumumab + bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma: analysis of minimal residual disease in the perseus trial. 
• s202 isatuximab, lenalidomide, bortezomib and dexamethasone for newly-diagnosed, transplant-eligible multiple myeloma: post transplantation interim analysis of the randomized phase iii gmmg-hd7 trial. 
• s204 daratumumab (dara) + bortezomib/thalidomide/dexamethasone (d-vtd) followed by dara maintenance in transplant-eligible (te) newly diagnosed multiple myeloma (ndmm): >6-year update of cassiopeia 
• s100 phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (isa-vrd) versus vrd for transplant-ineligible patients with newly diagnosed multiple myeloma (imroz).
•  s203 randomized phase 3 study of isatuximab (isa) plus lenalidomide and dexamethasone (rd) with bortezomib (v) versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (ndmm ti).
• s205 ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: cartitude-2 cohort d
• s208 idecabtagene vicleucel (ide-cel) in patients (pts) with clinical high-risk early relapse multiple myeloma (mm) without front-line (1l) autologous stem cell transplantation (asct): karmma-2 cohort 2b.
• s214 results from DREAMM-7 a randomized phase 3 study of belantamab mafodotin + bortezomib, and dexamethasone vs daratumumab + bortezomib, and dexamethasone in relpased/refractory multiple myeloma